Results of a new study show that IsoPSA, a novel prostate-specific antigen assay, is readily adopted by practitioners in various practice settings, and its use significantly reduces biopsies in men being evaluated for elevated PSA.
A new study aims to address racial disparities by examining the role of decision-making in Black patients’ attitudes about prostate cancer screening.
An article published in the Cleveland Clinic Journal of Medicine outlines current guidelines in prostate cancer screening from the lens of a urologist practicing in the UK.
Using the new 4Kscore test after a positive result from a traditional PSA test can reduce the number of prostate biopsies by 30 to 50 percent while still accurately identifying high-grade cancers.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic urologists are playing leading roles in the development of next-generation prostate cancer biomarkers. One new test under investigation, prostate specific antigen/solvent interaction analysis (PSA/SIA), shows promise in improving the diagnostic accuracy of screening and early detection strategies by differentiating PSA structural changes induced by cancer from those of benign glands.